References
- DeFrances CJ, Hall MJ, Podgornik MN. 2003 National Hospital Discharge Survey. Advance data from vital and health statistics; no 359. Hyattsville (MD): National Center for Health Statistics; 2005
- National Institutes of Health. Guidelines for the diagnosis and management of asthma. NIH Publication 97–4051 1997:1–152
- White MV, Sander N. Asthma from the perspective of the patient. J Allergy Clin Immunol 1999;104:S47–S52
- Penn RB, Frielle T, McCullough JR, et al. Comparison of R-, S-, and RS-albuterol interaction with human b1- and b2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37–45
- Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971;14:7–36
- Agrawal DK, Ariyarathna K, Kelbe PW. (S)-albuterol activates proconstrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004;113:503–10
- Ameredes BT, Calhoun WJ. Modulation of GM-CSF-release by enantiomers of b-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005;116:65–72
- Cho SH, Hartleroad JY, Oh CK. (S)-Albuterol increases the production of histamine and IL-4 mast cells. Int Arch Allergy Immunol 2001;124: 478–84
- Baramki D, Koester J, Anderson AJ, et al. Modulation of t-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;108:449–54
- Xopenex Inhalation Solution [package insert]. Marlborough, MA: Sepracor Inc.; 2005
- Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615–21
- Milgrom H, Skoner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108:938–45
- Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102:943–52
- Pleskow WW, Nelson HS, Schaefer K, et al. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004;25:429–36
- Carl JC, Myers TR, Kirchner LH, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatrics 2003;143:731–6
- Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med 2005;23:842–7
- Qureshi F, Zaritsky, A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005;46:29–36
- Berger WE. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Deliv 2005;2: 965–80
- World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc 1997;277:925–6
- American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152: 1107–56
- Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996;5:35–46
- Landgraf JM, Abetz L, Ware JE. Child Health Questionnaire (CHQ): a user’s manual. The Health Institute, New England Medical Center, Boston, MA
- Nowak R. Single-isomer levalbuterol: a review of the acute data. Current Allergy Asthma Reports 2003;3:172–8
- Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 2003;90:583–92
- Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001;108:681–4
- Asmus MJ, Hendeles L, Weinberger M, et al. Levalbuterol has not been established to have therapeutic advantages over racemic albuterol. J Allergy Clin Immunol 2002;100:325
- Chowdhury BA. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma. J Allergy Clin Immunol 2002;110:324
- Eaton EA, Waller UK, Wilson HM, et al. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol 1996;41:35–40
- Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996;41:35–40
- Dhand R, Goode M, Reid R, et al. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160:1136–41
- Henderson WR, Banerjee ER, Chi EY. Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immmunol 2005;116:332–40
- Nowak R, Emerman C, Hanrahan JP, et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006;24:259–67